Drug intelligence / Profile preview

PTX-142

Development stage: Preclinical
Lead developer: Pleco Therapeutics
Modality: Small Molecules

Overview

PTX-142 is a fixed-dose combination agent, classified as a Plecoid™ compound, under development by Pleco Therapeutics for the treatment of pancreatic cancer. It is being investigated as a chemical drug for its potential to improve outcomes in neoplasms, particularly pancreatic cancer. The precise mechanism of action has not been publicly disclosed; however, it is part of a pipeline focused on modulating tumor biology to enhance chemotherapy responsiveness. As of the latest updates, PTX-142 remains in preclinical development and has not yet entered clinical trials or received regulatory approval[1][2][7].

Beyond the preview

Go deeper on PTX-142.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-142.

Explore the full profile